ClinicalTrials.gov
ClinicalTrials.gov Menu

XIENCE V® USA Dual Antiplatelet Therapy (DAPT) Cohort (XVU-AV DAPT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01106534
Recruitment Status : Completed
First Posted : April 20, 2010
Results First Posted : June 28, 2016
Last Update Posted : June 28, 2016
Sponsor:
Collaborators:
Baim Institute for Clinical Research
Bristol-Myers Squibb
Eli Lilly and Company
Daiichi Sankyo, Inc.
Information provided by (Responsible Party):
Abbott Vascular

Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Conditions: Chronic Total Occlusion of Coronary Artery
Vascular Disease
Myocardial Ischemia
Coronary Artery Stenosis
Coronary Disease
Coronary Artery Disease
Coronary Restenosis
Interventions: Drug: placebo + aspirin
Drug: clopidogrel + aspirin OR prasugrel + aspirin
Device: XIENCE V Everolimus Eluting Coronary Stent System (XIENCE V EECSS)

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Additional 3000 patients were enrolled in the second enrollment phase and had completed phase I at 1 year. In phase II, 870 patients from these were transferred to AV-DAPT cohort and followed from 1 year to 33 months, and the remaining who did not participate in AV-DAPT cohort will be followed for the first year only.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment

Outcome measures of participants of XIENCE V USA trial of phase I followed up until 1 year from index procedure are available in the study with ID NCT00676520.

Outcome measures of participants belonging to XIENCE V USA long-term follow-up cohort of phase II (followed up from year 1 to year 5) are available in the study with ID NCT01120379.

Reporting Groups
  Description
Second Enrollment Phase of XIENCE V® USA Additional 3000 patients recruited in the second enrollment phase treated with the XIENCE V EECSS who are free from events (death, MI, repeat coronary revascularization, stroke, ST, or major bleeding - "severe" or "moderate" by GUSTO classification) in the first year after the index procedure, and are compliant with DAPT will be identified as prospective patients for the AV-DAPT cohort. A total of 870 Patients who are considered as part of the AV-DAPT cohort will continue with Aspirin therapy and will be randomized at 12 months post index procedure to 18 months of either active treatment with thienopyridines or placebo. Clinical follow-up will occur at 15, 24, 30 and 33 months. These patients will be followed by Abbott Vascular.

Participant Flow:   Overall Study
    Second Enrollment Phase of XIENCE V® USA
STARTED   2997 
COMPLETED   2960 
NOT COMPLETED   37 
Withdrawal by Subject                18 
Lost to Follow-up                2 
Death                16 
Physician Decision                1 



  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Baseline characteristics are provided for 2997 patients recruited in the second enrollment phase.

Reporting Groups
  Description
Second Enrollment Phase of XIENCE V® USA Additional 3000 patients recruited in the second enrollment phase treated with the XIENCE V EECSS who are free from events (death, MI, repeat coronary revascularization, stroke, ST, or major bleeding - "severe" or "moderate" by GUSTO classification) in the first year after the index procedure, and are compliant with DAPT will be identified as prospective patients for the AV-DAPT cohort. A total of 870 Patients who are considered as part of the AV-DAPT cohort will continue with Aspirin therapy and will be randomized at 12 months post index procedure to 18 months of either active treatment with thienopyridines or placebo. Clinical follow-up will occur at 15, 24, 30 and 33 months. These patients will be followed by Abbott Vascular.

Baseline Measures
   Second Enrollment Phase of XIENCE V® USA 
Overall Participants Analyzed 
[Units: Participants]
 		 2997 
Age 
[Units: Years]
Mean (Standard Deviation) 		 64.27  (10.39) 
Age, Customized 
[Units: Participants]
 		 
< 65 years   1587 
>= 65 to < 75 years   922 
>= 75 years   488 
Gender 
[Units: Participants]
 		 
Female   870 
Male   2127 
Race/Ethnicity, Customized [1] 
[Units: Participants]
 		 
American Indian or Alaskan Native   23 
Asian   49 
Black or African Heritage   231 
Native Hawaiian or Pacific Islander   7 
White   2577 
Hispanic or Latino   117 
Other   15 
[1] Patient may be counted in more than one category


  Outcome Measures

1.  Primary:   Incidence of Composite of All Death, MI and Stroke (Defined as MACE)   [ Time Frame: 12-33 months post-stent ]
  Show Outcome Measure 1

2.  Primary:   Incidence of ARC Definite or Probable ST   [ Time Frame: 12-33 months post-stent ]
  Show Outcome Measure 2

3.  Primary:   Major Bleeding (GUSTO Classification, Severe and Moderate Bleeding Combined)   [ Time Frame: 12-33 months post-stent ]
  Show Outcome Measure 3

4.  Secondary:   MACE for ITT Population   [ Time Frame: 12 through 30 months ]
  Show Outcome Measure 4

5.  Secondary:   ST for ITT Population   [ Time Frame: 12 through 30 months ]
  Show Outcome Measure 5

6.  Secondary:   Major Bleeding for ITT Population   [ Time Frame: 12 through 30 months ]
  Show Outcome Measure 6

7.  Secondary:   MACE for Treatment Population   [ Time Frame: 12 through 30 months and 12 through 33 months ]
  Show Outcome Measure 7

8.  Secondary:   ST for Treatment Population   [ Time Frame: 12 through 30 months and 12 through 33 months ]
  Show Outcome Measure 8

9.  Secondary:   Major Bleeding for Treatment Population   [ Time Frame: 12 through 30 months and 12 through 33 months ]
  Show Outcome Measure 9


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
The participants enrolled in this study will be followed by Abbott Vacular but their data will not be independently analyzed; they will only be analyzed as part of the DAPT study (NCT00977938) which is sufficiently powered for the outcomes.


  More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: David R Rutledge
Organization: Abbott Vascular
phone: (408) 845-3820
e-mail: david.rutledge@av.abbott.com



Responsible Party: Abbott Vascular
ClinicalTrials.gov Identifier: NCT01106534     History of Changes
Other Study ID Numbers: 06-374C
First Submitted: April 16, 2010
First Posted: April 20, 2010
Results First Submitted: July 31, 2015
Results First Posted: June 28, 2016
Last Update Posted: June 28, 2016